Fujian Haixi Pharmaceuticals (2637) Announces Changes to Joint Company Secretary and Authorized Representatives

Bulletin Express11-21

Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) (the “Company”) has announced that Ms. Chan Hiu Lam has resigned from her roles as a Joint Company Secretary, Authorized Representative under the Listing Rules and Companies Ordinance, as well as Process Agent, effective 21 November 2025. According to the announcement, Ms. Chan confirmed there is no disagreement with the board of directors, and no matter relating to her resignation requires the attention of the Stock Exchange or the shareholders.

Effective the same date, Ms. Lam Wai Yee Sophie will be appointed as Joint Company Secretary, Authorized Representative, and Process Agent. Ms. Lam brings more than 20 years of company secretarial and compliance experience, having provided services in similar capacities to various companies listed on the Main Board of the Stock Exchange. She will work alongside the current Joint Company Secretary, Ms. Zhang Junhuan.

Furthermore, the announcement notes that the Stock Exchange has granted a revised waiver regarding the qualification of Ms. Zhang to act as a Joint Company Secretary. The revised waiver is valid from 21 November 2025 to 19 October 2028, subject to the condition that Ms. Zhang be assisted by Ms. Lam during this period and that there be no material breach of the Listing Rules by the Company. Before the waiver expires, the Company must demonstrate that Ms. Zhang has attained the requisite experience to discharge the duties of a company secretary without further waiver.

The board expressed gratitude for Ms. Chan’s contributions and extended a welcome to Ms. Lam on her new appointments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118057854?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118057854","market":"us","top_or_hot":-1,"title":"Fujian Haixi Pharmaceuticals (2637) Announces Changes to Joint Company Secretary and Authorized Representatives","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) (the “Company”) has announced that Ms. Chan Hiu Lam has resigned from her roles as a Joint Company Secretary, Authorized Representative under the Listing Rules and Companies Ordinance, as well as Process Agent, effective 21 November 2025. According to the announcement, Ms. Chan confirmed there is no disagreement with the board of directors, and no matter relating to her resignation requires the attention of the Stock Exchange or the shareholders.</p>\n<p>Effective the same date, Ms. Lam Wai Yee Sophie will be appointed as Joint Company Secretary, Authorized Representative, and Process Agent. Ms. Lam brings more than 20 years of company secretarial and compliance experience, having provided services in similar capacities to various companies listed on the Main Board of the Stock Exchange. She will work alongside the current Joint Company Secretary, Ms. Zhang Junhuan.</p>\n<p>Furthermore, the announcement notes that the Stock Exchange has granted a revised waiver regarding the qualification of Ms. Zhang to act as a Joint Company Secretary. The revised waiver is valid from 21 November 2025 to 19 October 2028, subject to the condition that Ms. Zhang be assisted by Ms. Lam during this period and that there be no material breach of the Listing Rules by the Company. Before the waiver expires, the Company must demonstrate that Ms. Zhang has attained the requisite experience to discharge the duties of a company secretary without further waiver.</p>\n<p>The board expressed gratitude for Ms. Chan’s contributions and extended a welcome to Ms. Lam on her new appointments.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fujian Haixi Pharmaceuticals (2637) Announces Changes to Joint Company Secretary and Authorized Representatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFujian Haixi Pharmaceuticals (2637) Announces Changes to Joint Company Secretary and Authorized Representatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-21 16:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) (the “Company”) has announced that Ms. Chan Hiu Lam has resigned from her roles as a Joint Company Secretary, Authorized Representative under the Listing Rules and Companies Ordinance, as well as Process Agent, effective 21 November 2025. According to the announcement, Ms. Chan confirmed there is no disagreement with the board of directors, and no matter relating to her resignation requires the attention of the Stock Exchange or the shareholders.</p>\n<p>Effective the same date, Ms. Lam Wai Yee Sophie will be appointed as Joint Company Secretary, Authorized Representative, and Process Agent. Ms. Lam brings more than 20 years of company secretarial and compliance experience, having provided services in similar capacities to various companies listed on the Main Board of the Stock Exchange. She will work alongside the current Joint Company Secretary, Ms. Zhang Junhuan.</p>\n<p>Furthermore, the announcement notes that the Stock Exchange has granted a revised waiver regarding the qualification of Ms. Zhang to act as a Joint Company Secretary. The revised waiver is valid from 21 November 2025 to 19 October 2028, subject to the condition that Ms. Zhang be assisted by Ms. Lam during this period and that there be no material breach of the Listing Rules by the Company. Before the waiver expires, the Company must demonstrate that Ms. Zhang has attained the requisite experience to discharge the duties of a company secretary without further waiver.</p>\n<p>The board expressed gratitude for Ms. Chan’s contributions and extended a welcome to Ms. Lam on her new appointments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1118057854","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118057854","pubTimestamp":1763714671,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) (the “Company”) has announced that Ms. Chan Hiu Lam has resigned from her roles as a Joint Company Secretary, Authorized Representative under...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"福建海西药业(2637)公布联席公司秘书及授权代表变动","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) (the “Company”) has announced that Ms. Chan Hiu Lam has resigned from her roles as a Joint Company Secretary, Authorized Representative under the Listing Rules and Companies Ordinance, as well as Process Agent, effective 21 November 2025. According to the announcement, Ms. Chan confirmed there is no disagreement with the board of directors, and no matter relating to her resignation requires the attention of the Stock Exchange or the shareholders.\nEffective the same date, Ms. Lam Wai Yee Sophie will be appointed as Joint Company Secretary, Authorized Representative, and Process Agent. Ms. Lam brings more than 20 years of company secretarial and compliance experience, having provided services in similar capacities to various companies listed on the Main Board of the Stock Exchange. She will work alongside the current Joint Company Secretary, Ms. Zhang Junhuan.\nFurthermore, the announcement notes that the Stock Exchange has granted a revised waiver regarding the qualification of Ms. Zhang to act as a Joint Company Secretary. The revised waiver is valid from 21 November 2025 to 19 October 2028, subject to the condition that Ms. Zhang be assisted by Ms. Lam during this period and that there be no material breach of the Listing Rules by the Company. Before the waiver expires, the Company must demonstrate that Ms. Zhang has attained the requisite experience to discharge the duties of a company secretary without further waiver.\nThe board expressed gratitude for Ms. Chan’s contributions and extended a welcome to Ms. Lam on her new appointments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118057854","isCrawlerRequest":true}